Biotech | December 08, 2025
Freenome strikes SPAC deal to go public in 2026
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
76 of 180 long COVID-associated genes also linked to ME
It's an acquisition that aims at forming one of the US's largest oncology trial networks
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
Subscribe To Our Newsletter & Stay Updated
